[ad_1] Story developing. Stay tuned for updates here. The numbers: The Philadelphia Fed said Thursday…
Tag:
Healthcare/Life Sciences
-
-
STOCK MARKET
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
by userby user[ad_1] UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of…
-
STOCK MARKET
Want to up your brain game? Here are some ways to fend off cognitive decline.
by userby user[ad_1] These days, my husband and I find ourselves relying on each other to finish…
-
STOCK MARKET
CVS closing some pharmacies in Target stores, in the latest industry pullback
by userby user[ad_1] CVS Health Corp. on Thursday said it would close “select” pharmacies set up in…
-
STOCK MARKET
Blood-plasma group’s shares rally after short seller slashes negative bet
by userby user[ad_1] Shares of Grifols rallied 8% on Wednesday, after the short-seller who criticized the Spanish…
-
STOCK MARKET
What is Wegovy worth to your employer? Companies wrestle with obesity drugs’ costs, long-term value.
by userby user[ad_1] Amid mounting evidence of obesity drugs’ longer-term health benefits, thorny questions persist about their…
-
STOCK MARKET
The history of tech holds a big warning for Nvidia, Microsoft and other AI plays, says this storied investor
by userby user[ad_1] Terry Smith, the fund manager of the £23.7 billion ($30 billion) Fundsmith Equity Fund,…
-
STOCK MARKET
GSK to buy asthma drug developer for up to $1.4 billion in pipeline push
by userby user[ad_1] GSK on Tuesday said it had struck a deal to acquire asthma drug developer…
-
STOCK MARKET
Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships
by userby user[ad_1] Nvidia Corp. NVDA, +4.88% is doubling down on artificial-intelligence-powered drug discovery and development, announcing…
-
STOCK MARKET
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
by userby user[ad_1] The Russell 2000 Index soared 12% in December, which might reflect investors’ exuberance about…